Peet Serfontein & Khumbulani Kunene
We enter a long position with a target price of $400.00 and a stop-loss of $310.00.
Insulet Corporation is a medical device company dedicated to simplifying life for people living with diabetes through the use of its Omnipod technologies, a tubeless insulin delivery device.
Insulet has established a strong position in the wearable medical device market by combining automation, convenience, and user-centred design to simplify insulin management.
Technically, a steep, rising channel (see the black parallel trendlines on the main chart) has been in place since May 2024 and reflects a well-established upward trend defined by progressively higher highs and higher lows. As the current price sits near the lower boundary of this channel, it can be interpreted as a bullish support zone because the lower trendline represents an area where buyers have reliably stepped in throughout the life of the pattern.
The insert show AI model based on forward calculated price targets for the stock. The model downloads seven years of price data, cleans and adjusts it for corporate actions and then builds a wide range of technical indicators. The recent price shows a steady recovery, and the model projects a continued upward bias across the one-, three-, six- and 12-month horizons, supporting the bullish stance.
Fading downside price momentum per the MACD histogram and the recent sideways trajectory of the on-balance volume (OBV) indicator also supports our bullish view.
| Share Information | |
|---|---|
| Share Code | PODD |
| Industry | Health Care Equipment & Service |
| Market Capital (USD) | 23.46 |
| One Year Total Return | 27.28% |
| Return Year-to-date | 27.73% |
| Current Price (USD) | 333.47 |
| 52 Week High (USD) | 353.50 |
| 52 Week Low (USD) | 230.05 |
| Financial Year End | December |
| The price remains above its 200-day simple moving average (SMA), and this also supports the bullish case for the stock. | |
| Consensus Expectations (Bloomberg) | ||||
|---|---|---|---|---|
| FY24 | FY25E | FY26E | FY27E | |
| Headline Earnings per Share (USD) | 3.24 | 4.77 | 6.12 | 7.68 |
| Growth (%) | 47.13 | 28.47 | 25.46 | |
| Dividend Per Share (USD) | 0.00 | 0.00 | 0.00 | 0.00 |
| Growth (%) | - | - | - | |
| Forward PE (times) | 69.95 | 54.45 | 43.40 | |
| Forward Dividend Yield (%) | 0.00 | 0.00 | 0.00 | |
| The company is set to achieve strong double-digit earnings growth in the medium-term, which is encouraging. | ||||
Buy/Sell Rationale:
Technical Analysis:
Fundamental view:
| Share Name and Position | COST - Stop loss (Close the position) |
ETN - Buy (Continue to hold) |
KR - Buy (Continue to hold) |
PRU - Buy (Continue to hold) |
|---|---|---|---|---|
| Entry | 937.50 | 334.86 | 66.88 | 105.04 |
| Current Price | 895.08 | 338.29 | 67.38 | 102.64 |
| Movement | -4.5% | +1.0% | +0.7% | -2.3% |
| Comment | The stock hit our stop-loss level, prompting us to close the position. |
A price developing wave b of the Elliott Wave price theory remains of interest. Testing its 200-day SMA. Downside price momentum is a concern.
Our profit target is $395.00 with a trailing stop-loss at $314.00. |
A developing rising wedge pattern remains of interest. Remains below its 200-day simple moving average. Fading downside price momentum is supportive.
Our profit target is $76.00 with a trailing stop-loss at $63.30. |
The bullish momentum signal from the Fisher Transform indicator remains of interest. Testing its 200-day simple moving average. Upside price momentum halted is a concern.
Our profit target is $116.00 with a trailing stop-loss at $100.50. |
| Time to exit | - | 28 April 2026 | 26 January 2026 | 4 February 2026 |
| Share Name and Position | BSX - Buy (Continue to hold) |
OTIS - Buy (Continue to hold) |
ABNB - Buy (Continue to hold) |
|---|---|---|---|
| Entry | 102.50 | 91.43 | 122.89 |
| Current Price | 99.22 | 87.70 | 115.42 |
| Movement | -3.2% | -4.1% | -6.1% |
| Comment |
The De-Trended Price Oscillator (DPO) remains of interest. Dipped below its 200-day SMA. The start of downside price momentum is a concern.
Our profit target is $118.00 with a trailing stop-loss at $96.30. |
The formation of a developing symmetrical triangle pattern remains of interest. Remains below its 200-day SMA. Fading upside price momentum is a concern.
Our profit target is $100.00 with a trailing stop-loss at $88.00. |
A developing symmetrical triangle pattern remains of interest. Remains below its 200-day simple moving average. Downside price momentum is a concern.
Our profit target is $141.00 with a trailing stop-loss at $116.00. |
| Time to exit | 20 February 2026 | 17 December 2025 | 29 December 2025 |
FNB Stockbroking and Portfolio Management (Pty) Ltd, a subsidiary of FirstRand Bank Limited, an authorised Financial Services Provider and authorised user of the JSE limited (Reg no: 1996/011732/07). This Publication note is issued by FNB Stockbroking and Portfolio Management (Pty) Ltd for the information of clients only and should not be produced in whole or part without prior permission. Although FNB Stockbroking and Portfolio Management (Pty) Ltd is an Authorised Financial Services Provider, any opinions and/or analysis contained in this Publication are for informational purposes only and should not be considered advice, including but not limited to financial, legal or tax advice, or a recommendation to invest in any security or to adopt any investment strategy. The information contained herein has been obtained from sources/persons which we believe to be reliable but is not guaranteed for correctness, completeness or otherwise and we do not assume liability for loss arising from errors in the information or that may be suffered from using or relying on the information contained herein irrespective of whether there has been any negligence by us, our affiliates or any other employees of us, and whether such losses be direct or consequential. As market and economic conditions are subject to rapid change, any comments, opinions, and analysis is rendered as of the date of publishing and may change without notice. Such changes may have a material impact on the outcome of any investment. Securities involve a degree of risk and are volatile instruments. Past performance is not indicative of future performances. Securities or financial instruments mentioned in the Publication note may not be suitable for all investors and FNB Stockbroking and Portfolio Management (Pty) Ltd has bares no responsibility whatsoever arising from or as a consequence hereof. The material is not intended as a complete analysis of every material fact regarding any share, instrument, sector, region, market, country, investment, or strategy. The recipient of this Publication must make their own investment decision and is advised to contact his relationship manager for a personal financial analysis prior to making any investment decisions. Copyright 2018 by FNB Stockbroking and Portfolio Management (Pty) Ltd.
